J.P. Morgan Appointed Depositary Bank By China Nuokang Bio-Pharmaceutical

Hong Kong, January 14, 2010 – J.P. Morgan announced today that it has been appointed depositary bank by China Nuokang Bio-Pharmaceutical Inc. (‘Nuokang’) in connection with Nuokang’s recent initial public offering of 5,000,000 American Depositary Shares.

Nuokang is a leading bio-pharmaceutical company in China, focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. The company provides a diversified portfolio of products to more than 2,400 hospitals in China.

“Throughout the entire IPO process, J.P. Morgan’s depositary receipts team was extremely responsive to our needs. We look forward to partnering with J.P. Morgan to further develop our ADR program and to support our business expansion going forward,” said Xue Baizhong, chairman and chief executive officer of China Nuokang Bio-Pharmaceutical.

“We are pleased to be appointed depositary bank by China Nuokang. We believe that our extensive experience in helping China-based companies enter the U.S. market will be instrumental in the continued success of Nuokang’s ADR program,” added Kenneth Tse, Asia Pacific head of J.P. Morgan’s depositary receipts group

J.P. Morgan is committed to working closely with its clients to design and implement customized depositary receipt (‘DR’) programs to achieve their strategic goals and facilitate DR liquidity.

Download: J.P. Morgan Appointed Depositary Bank By China Nuokang Bio-Pharmaceutical PDF


Download the latest version of Adobe Reader  English

A link to this article will be included in your message to the recipient. Fields with an * are required.

To (e-mail address - use a comma between multiple addresses)*

From (your e-mail address)*

Subject line

The e-mail addresses entered on this page will not be used to send unsolicited e-mail and will not be sold to a third party. For additional information, view our privacy and security policy.